eigerbioadmin

Home»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 166 blog entries.
7 01, 2020

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer

2020-01-07T14:48:46+00:00

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer Launch Preparation Underway for Lonafarnib in Progeria Market Development Activities Advancing for HDV Program PALO ALTO, Calif., January 7, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies [...]

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer2020-01-07T14:48:46+00:00
6 01, 2020

Eiger Updates on 2019 Progress and 2020 Milestones Expected

2020-01-06T14:59:42+00:00

Eiger Updates on 2019 Progress and 2020 Milestones Expected Progeria Rolling NDA Planned for Completion in 1Q 2020 HDV Phase 3 D-LIVR Study Enrollment Planned to Complete in 2020 Commercial Focus on Progeria Launch Preparation and HDV Market Building Strong Balance Sheet with ~$95M in Cash and Investments to Begin 2020 PALO ALTO, Calif., [...]

Eiger Updates on 2019 Progress and 2020 Milestones Expected2020-01-06T14:59:42+00:00
17 12, 2019

Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

2019-12-17T00:20:58+00:00

Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies Rolling NDA Submission Planned for Completion in First Quarter 2020 Marketing Authorization Application (MAA) to EMA Planned in First Quarter 2020 PALO ALTO, Calif., December 16, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late [...]

Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies2019-12-17T00:20:58+00:00
15 11, 2019

Eiger to Present at Jefferies 2019 London Healthcare Conference

2019-11-15T17:27:31+00:00

Eiger to Present at Jefferies 2019 London Healthcare Conference PALO ALTO, Calif. – November 15, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies 2019 London Healthcare Conference on November [...]

Eiger to Present at Jefferies 2019 London Healthcare Conference2019-11-15T17:27:31+00:00
12 11, 2019

Eiger Announces Peginterferon Lambda – Lonafarnib Combination Interim Results

2019-11-12T21:55:21+00:00

Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019 53% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 Median Decline of HDV RNA: -3.4 Log at Week 24 95% of Patients Achieve > [...]

Eiger Announces Peginterferon Lambda – Lonafarnib Combination Interim Results2019-11-12T21:55:21+00:00
7 11, 2019

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

2019-11-07T21:42:42+00:00

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update Successful Pre-NDA and Pre-MAA Meetings for Progeria & Progeroid Laminopathies Positive Phase 2 LIFT Lambda Combo Data as Late-Breaker at AASLD First-Ever Phase 3 HDV International D-LIVR Study Enrolling and Dosing Strong Balance Sheet with $109.9M in Cash & Investments PALO ALTO, [...]

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update2019-11-07T21:42:42+00:00
21 10, 2019

Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019

2019-10-21T14:08:32+00:00

Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019rectors >50% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24Median Decline of HDV RNA: -3.4 Log at Week 2495% of Patients Achieve >2 Log Decline in HDV [...]

Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 20192019-10-21T14:08:32+00:00
28 09, 2019

Eiger to Present at Cantor 2019 Global Healthcare Conference

2019-09-28T15:38:30+00:00

Eiger to Present at Cantor 2019 Global Healthcare Conference PALO ALTO, Calif. – September 27, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Cantor 2019 Global Healthcare Conference on October [...]

Eiger to Present at Cantor 2019 Global Healthcare Conference2019-09-28T15:38:30+00:00
29 08, 2019

Eiger BioPharmaceuticals to Participate in September Conferences

2019-08-29T20:16:25+00:00

Eiger BioPharmaceuticals to Participate in September Conferences PALO ALTO, Calif. – August 29, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in the following upcoming investor conferences in September: Baird 2019 Global Healthcare Conference at the [...]

Eiger BioPharmaceuticals to Participate in September Conferences2019-08-29T20:16:25+00:00
20 08, 2019

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection

2019-08-20T12:48:11+00:00

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection Fourth Eiger Program Granted Breakthrough Therapy Designation PALO ALTO, Calif., August 20, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and [...]

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection2019-08-20T12:48:11+00:00
Eiger BioPharmaceuticals © 2018 | All Rights Reserved
Toggle Sliding Bar Area